Disclosed herein are methods of identifying a cancer characterized by aberrant ROS1 activity as being crizotinib resistant and foretinib (N1'-[3-fluoro-4-[[6-methoxy-7-(3-morpholinopropoxy)-4-quinolyl]oxy]phenyl]-N1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide) sensitive through the identification of mutations in the kinase domain of ROS1. Also disclosed kits used in facilitating the method as well as pharmaceutical compositions comprising foretinib for use in treating cancers characterized by aberrant ROS1 activity.
METHODS OF TREATING CANCERS CHARACTERIZED BY ABERRENT ROS1 ACTIVITY